Overview

Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Status:
Completed

Trial end date:
2016-02-23

Target enrollment:

Participant gender:

Summary

The purpose of this study is to find out if immunotherapy (rituximab) added to chemotherapy is a safe treatment for primary central nervous system lymphoma (PCNSL). PCNSL is a rare tumor. It is usually treated with chemotherapy and radiation. This combination prolongs survival, but about half of patients relapse. The investigators hope that the addition of rituximab will improve the control of the tumor.

Phase:

N/A

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Collaborators:

Columbia University
Kentuckiana Cancer Institute
Northwestern Memorial Hospital
University of Vermont
University of Virginia

Treatments:

Cytarabine
Leucovorin
Methotrexate
Procarbazine
Rituximab
Vincristine